Navigation Links
Uroplasty, Inc. Announces Pricing of a Public Offering of Its Common Stock
Date:11/20/2007

MINNEAPOLIS, Nov. 20 /PRNewswire-FirstCall/ -- Uroplasty, Inc. (Amex: UPI) announced today the pricing of its public offering of 1,466,400 shares of its common stock. The offering was priced at $3.50 per share. Uroplasty has granted the underwriters a 30-day option to purchase up to an additional 219,960 shares of common stock at the offering price to cover over-allotments. The proceeds from the sale of shares will be used primarily to expand its sales and marketing organization in the United States, to conduct clinical studies to support its marketing efforts and for working capital purposes.

Craig-Hallum Capital Group LLC is serving as bookrunning lead manager for the offering with Noble International Investments, Inc. acting as co-manager. A copy of the final prospectus related to this offering may be obtained by contacting Craig-Hallum Capital Group, Prospectus Department, 222 South Ninth Street, Suite 350, Minneapolis, MN 55402 (Tel: 1-800-752-1476).

A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state. Any offer or sale will be made only by means of the written prospectus forming a part of the effective registration statement.

Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our primary focus is the commercialization of our Urgent PC(R) system, which we believe is the only FDA-approved non-surgical neurostimulation therapy for the treatment of overactive bladder symptoms (OAB). We also offer Macroplastique(R) Implants, a bulking agent for the treatment of urinary incontinence.

For Further Information:

Uroplasty, Inc. EVC Group

David Kaysen, President and CEO, or Douglas Sherk (Investors)

Medi Jiwani, Vice President, CFO, 415.896.6820

and Treasurer, Julie Huang (Investors)

952.426.6140 646.443.6963

Jennifer Saunders (Media)

646.201.5431


'/>"/>
SOURCE Uroplasty, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Uroplasty, Inc. Announces Filing of Registration Statement for Offering of Common Stock
2. Uroplasty, Inc. Reports Record Sales For Second Fiscal Quarter
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... LabRoots ... scientists from around the world, announces the launch of its newly redesigned website. ... portal to research breakthroughs and trending news, vital information on upcoming virtual events ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... telemedicine solutions, has recently unveiled impressive transportable capabilities with their iMedHD2™ Portable ... is an extension to RMT technology that delivers HD, dynamic, streaming ultrasound images ...
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth ... this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present ... the clinic’s leading recovery program. , “We know it’s easy to get ...
(Date:1/19/2017)... ... January 19, 2017 , ... Dr. Andrew Lian-Jie ... fellowship trained Mohs and cosmetic surgeon. After extensive dermatology research training at the ... internship in internal medicine at the Emory University and dermatology training at the ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... Clinical Conductor CTMS, which provides a modern CTMS workflow designed to seamlessly integrate ... information has been condensed to a single page, maximizing usability and improving efficiency ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, ... anti-obesity drugs market is expected to grow at a CAGR ... CAGR of 38.7% in the second half of the forecast period. ... from 2016 to 2027. The market is estimated at $1,058 million ... ...
(Date:1/19/2017)... LONDON , January 19, 2017 ... Grothey ; European Oncology & Haematology, 2016;12(Suppl 2):3-8; ... ... http://photos.prnewswire.com/prnh/20151014/276718LOGO) Published recently in ... the peer-reviewed journal from touchONCOLOGY, an article by ...
(Date:1/19/2017)... PALO ALTO, Calif. , Jan. 19, 2017 /PRNewswire/ ... scientific research, is excited to announce that the ... Project: Cancer Biology  (RP:CB) have been published in ... science, this project represents the first practical evaluation ... that result in reproducible studies. Unlike other assessments ...
Breaking Medicine Technology: